Viibryd is the brand name for vilazodone, a prescription antidepressant used to treat major depressive disorder in adults. Employees who take Viibryd sometimes worry that a routine workplace drug screen will flag the medication, delay a job offer, or cause an awkward conversation with a supervisor. This guide looks at what vilazodone actually is, which drug classes standard workplace panels are built to detect, and why vilazodone is not one of them. It also explains the role of the medical review officer and why keeping prescription documentation on hand still matters, even for a drug that is not a target analyte.
What Viibryd (vilazodone) actually is
According to the product labeling on DailyMed, vilazodone is classified as a serotonin reuptake inhibitor and partial agonist at the 5-HT1A receptor. That combined mechanism is why it is sometimes described as an SSRI with an added partial agonist action, rather than a plain SSRI like sertraline or fluoxetine. The National Library of Medicine's consumer drug reference, MedlinePlus, describes vilazodone as a medication for depression that works by increasing the amount of serotonin available in the brain, and it lists the typical warnings that apply to this medication class, including the boxed warning about suicidal thinking in younger patients and the need to take the tablet with food.
Vilazodone is not a federally controlled substance under the Controlled Substances Act schedules. It carries no abuse potential classification the way a benzodiazepine or a stimulant does, and it is not chemically related to opioids, amphetamines, benzodiazepines, barbiturates, phencyclidine, or cannabinoids, the drug classes that make up most standard screening panels.
What a standard workplace drug panel actually targets
Workplace drug testing programs, whether they follow the federal model for safety sensitive transportation employees or a private employer's own policy, are built around a defined list of target drug classes. The eCFR text of 49 CFR Part 40, Subpart F lists the drugs and drug metabolites that federally regulated testing laboratories are required to analyze for, and vilazodone is not among them. The same is true of the broader federal workplace drug testing framework described by the Substance Abuse and Mental Health Services Administration, which oversees certified laboratories and sets the scientific and technical guidelines agencies and many private employers rely on. SAMHSA's drug free workplace program page explains that standard panels are designed around specific drug classes, not around every prescription medication an employee might be taking.
A typical 5 panel, 10 panel, or 12 panel immunoassay cup or dip card is manufactured to react with antibodies tuned to amphetamines, cocaine metabolites, opiates, PCP, THC, and depending on the panel size, benzodiazepines, barbiturates, methadone, and a handful of other classes. Vilazodone's chemical structure does not resemble any of those target classes closely enough to be an expected source of cross reactivity on an immunoassay screen. There is no published, peer reviewed cross reactivity data showing vilazodone triggers a false positive on any standard immunoassay panel, and no FDA labeling or SAMHSA guidance identifies it as an interferent.
| Panel class tested | Is vilazodone (Viibryd) part of this class | Expected result on a standard screen |
|---|---|---|
| Amphetamines / methamphetamine | No | Not expected to trigger a positive |
| Opiates / opioids | No | Not expected to trigger a positive |
| Benzodiazepines | No | Not expected to trigger a positive |
| Cannabinoids (THC) | No | Not expected to trigger a positive |
| Cocaine metabolite | No | Not expected to trigger a positive |
| PCP, barbiturates, methadone | No | Not expected to trigger a positive |
Screening versus confirmation, and why it matters here
Every credible workplace drug testing program uses a two step process. The first step is an immunoassay screen, run on a cup, dip card, or oral fluid device, that flags specimens above a cutoff concentration for a target drug class. The second step, used only on specimens that screen positive, is confirmation testing by gas chromatography mass spectrometry or liquid chromatography mass spectrometry. Confirmation testing identifies the exact molecule present, which is why it is the method toxicologists and medical review officers rely on when a result is contested.
Because vilazodone is not a target analyte for either step, it would not be expected to produce a screen flag in the first place, and it is not something a standard confirmation panel is even looking for. If an employee on Viibryd ever did screen positive for an unrelated class, that would point toward investigating another cause, not toward the antidepressant. This is a case where the honest answer is that there is no published cross reactivity evidence connecting vilazodone to a false positive on any standard panel, not a case of "limited evidence suggests."
How Viibryd compares with other antidepressants employers ask about
Employers and employees researching this topic often come across similar questions about other antidepressants, and the answers are not identical across the class. Bupropion, sold under brand names including Wellbutrin, has documented cross reactivity with amphetamine immunoassay screens and is a well known source of false positives on that panel. Trazodone and some tricyclic antidepressants have also been associated with occasional immunoassay interference in published case reports. Vilazodone is chemically distinct from bupropion and from the tricyclic class, and the DailyMed label does not list any drug screening interference among its documented interactions or precautions. That distinction is worth noting because it means a blanket statement like "antidepressants cause false positives" does not hold for every medication in the class, and vilazodone specifically has no published record of causing one.
This is also why confirmation testing exists. Even in drug classes where a prescription medication is a known interferent, GC/MS or LC/MS confirmation can distinguish the specific molecule present in a specimen from the target drug the panel was designed to catch. For a medication like vilazodone, where there is no known interference to begin with, confirmation testing simply is not a step that would ordinarily come into play.
The medical review officer process still matters
Even though vilazodone is not expected to affect panel results, any employee taking a prescription medication should keep that prescription documented and be ready to disclose it if asked. In regulated testing programs, a certifying scientist reviews any nonnegative result before it reaches a medical review officer, a licensed physician trained to interpret test results in light of an employee's legitimate medical explanations. If a specimen were ever to screen positive for a reason unrelated to Viibryd, the medical review officer would be the one to contact the employee, review the prescription, and determine whether the result has a legitimate medical explanation before any verified result is reported to an employer. This process exists precisely so that a prescribed medication is never confused with an unauthorized substance, and it is not a step an employee or employer should try to bypass or guess their way around.
Employers designing or administering a drug free workplace policy should route every nonnegative result through this chain rather than making employment decisions directly off a screening cup or dip card result. Decisions about discipline, continued employment, or accommodation for a legitimate prescription generally involve human resources and, where ADA or similar protections may apply, legal counsel, since those determinations vary by state and by the specific facts involved.
Frequently asked questions
Will Viibryd make me fail a drug test?
No standard workplace immunoassay panel is designed to detect vilazodone, and there is no published cross reactivity evidence linking it to a false positive on amphetamine, opiate, benzodiazepine, THC, cocaine, or PCP screens. It generally would not be expected to affect the result of a routine panel.
Is vilazodone a controlled substance?
No. Vilazodone is not scheduled under the Controlled Substances Act and carries no federal controlled substance classification, unlike benzodiazepines or stimulant medications.
Do I need to tell my employer I take Viibryd?
Policies vary by employer and by state. In regulated testing programs, prescription disclosure generally happens through the medical review officer if a question ever arises, not as a blanket requirement before testing. Keeping current prescription documentation on hand is a reasonable precaution regardless.
What drug classes does a standard 10 panel or 12 panel test actually check for?
Typical panels target classes such as amphetamines, cocaine metabolites, opiates, THC, PCP, benzodiazepines, barbiturates, and methadone. Antidepressants in general, including SSRIs and vilazodone specifically, are not part of these target classes.
What happens if a test result comes back positive while I am taking Viibryd?
Any nonnegative result in a regulated program is reviewed by a certifying scientist and then a medical review officer before it is reported. The medical review officer would investigate the specific drug class that triggered the result and review any prescription documentation, since vilazodone itself is not the expected cause of a flagged result.
Where can employers find the official list of drugs a federal workplace panel tests for?
The drug classes and procedures for federally regulated transportation testing are published in 49 CFR Part 40, Subpart F on eCFR, and SAMHSA maintains broader program guidance for federal and many private sector workplace testing programs.
Related reading
- Does Lexapro Show Up on a Drug Test? Escitalopram and Screening Panels
- Does Pristiq Show Up on a Drug Test? Desvenlafaxine and False Positive Risk
Employers building or restocking a drug free workplace program can review cup, dip card, and oral fluid options through the American Screening Corporation wholesale portal.
This article is general information only and is not legal or medical advice. Employers should consult qualified counsel and a medical review officer for decisions involving specific employees or testing programs.
